Pyrotinib in combination with Capecitabine.

Phase 3

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JNGHF)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

10mo

JNGHFPhase 3

Pyrotinib in combination with Capecitabine. Phase 3 Results Expected

Pyrotinib in combination with Capecitabine.• HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane381

Dec 31Estimated

CT.gov

00%

Competitive Landscape

0 competitors in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

View Full Landscape

Drug Information

Target Indication

HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Clinical Trial

NCT05424835

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

JNGHF

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Biotechnology•North America•NASDAQ

Related Pipeline

X0002 SprayPhase 3

KNEE OSTEOARTHRITIS

Nalbuphine Hydrochloride InjectionPhase 3

Postoperative Analgesia

ApatinibPhase 3

Carcinoma, Hepatocellular

HRS-4357 injectionPhase 3

PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer

MorphinePhase 3

Pain

View full pipeline